Life Sciences

Life sciences firm SBH Sciences of Natick is linking up with a Georgia company in a collaborative venture to research and develop a class of drugs that can treat a variety of diseases, the two firms announced.

Marlborough-based Advanced Cell Technology announced today that CEO Gary Rabin is leaving his position, and his seat on the company's Board of Directors, effective immediately.

HeartWare International said Tuesday that its fourth-quarter revenue may fall short of market expectations.

A ban on U.S. sales of the Guidezilla catheter made by Boston Scientific (BSX) went into effect yesterday after a federal appeals court ruled against BSX's petition for an interim stay.

Biotech giant Genzyme has bought a 12-percent stake in Cambridge-based Alnylam Pharmaceuticals in an investment valued at $700 million, Genzyme announced today.

Medical diagnostics firm Oxford Immunotec of Marlborough said revenues for its most recent quarter and for 2013 are up by nearly double over the previous year.

The University of Massachusetts Medical School (UMMS) has announced it will receive $100,000 over the next two years to develop an antibody for a genetic condition that can cause emphysema and liver disease.

Advanced Cell Technology of Marlborough agreed last week to pay $4.1 million over the next 18 months to settle claims by the U.S. Securities and Exchange Commission that the biotechnology firm sold billions of shares of unregistered penny stocks.

The decision to take a company public isn't an easy one, said Paul Brannelly, senior vice president of finance and administration at Karyopharm Therapeutics in Natick. The money and time spent on activities related to public trading are considerable, according to Brannelly. Being public somewhat limits executives' ability to make quick business decisions. But Karyopharm, a clinical-stage drug company that is developing treatments for solid tumors as well as cancers of the blood, saw pursuing an initial public offering (IPO) this fall as an opportunity to shore up financing as it continues the lengthy clinical trial process that it hopes will lead to approval from the U.S. Food and Drug Administration (FDA).

Biopharmaceutical manufacturing could be a major economic boon for the Worcester area, according to a PricewaterhouseCoopers study...